CG Oncology's cretostimogene cut bladder cancer recurrence 68% in Phase 3 trial
CG Oncology said Monday that cretostimogene, an immunotherapy infused directly into the bladder, reduced the risk of tumor recurrence by 68% compared with current medical practice in a randomized Phase 3 trial of 367 patients with intermediate-risk bladder cancer. The treatment is built from a common cold virus engineered to target cells carrying a specific mutation found in bladder tumors; delivered by catheter, it enters those cells, replicates rapidly and ruptures them. The figures are topline results announced by the company, not peer-reviewed data, and the available report does not give absolute recurrence rates, a statistical significance measure, or safety results. Intermediate-risk bladder cancer is a localized form that is usually removed surgically and then monitored every three months, with repeat procedures if the cancer returns.
Verified and unconfirmed
- Verified: CG Oncology announced topline results from a randomized Phase 3 trial in 367 patients with intermediate-risk bladder cancer showing a 68% reduction in recurrence risk versus current medical practice, according to the company as reported by STAT+.
- Not yet confirmed: the absolute recurrence rates behind the relative 68% figure, statistical significance, durability and safety data, and whether the results have been submitted for regulatory review — all rest on the company’s announcement, with no peer-reviewed publication or independent verification in the supplied material.
Background
Cretostimogene belongs to a class called oncolytic viruses: a common cold virus engineered to enter cells carrying a specific mutation found in bladder tumors, replicate inside them and burst them open. Because the bladder is a hollow organ, the therapy can be infused directly through a catheter rather than delivered systemically. The patients in this trial have intermediate-risk bladder cancer, a localized form of the disease that is usually removed with a minimally invasive operation and then checked every three months; if tumors return, surgery can be repeated, but repeated procedures eventually cost patients bladder function while the cancer can keep growing.
Why it matters
For these patients the current path is repeated surgery and monitoring rather than a drug, so a therapy that delays recurrence could postpone the loss of bladder function that comes with successive procedures — but because the 68% is a relative risk reduction, clinicians cannot judge the actual benefit without the absolute event rates and safety data that the announcement leaves out.
Comments
Comments use a GitHub account and are moderated. Comment rules